The Finland-based company inked a new sales and distribution agreement with Tri-State Biologics (TSB). New Jersey-based TSB distributes medical and surgical products, with 18 sales representatives aiding in medical device distribution. This agreement comes as a continuation of a previously signed logistics agreement with GlobalMed Logistix.
Bioretec said the agreement enables the smooth sales and distribution of implants and instrument sets to hospitals within Greater New York City, Philadelphia, New Jersey, Connecticut and Massachusetts. The company says it covers one of the most populated areas across the U.S.
As part of the next phase of its RemeOs, Bioretec wants to sign more new local sales and distribution agreements. It aims to serve civilian hospitals in the U.S., while partner Spartan Medical continues serving military and veteran hospitals.
“We are happy to announce this sales and distribution agreement with a partner who is innovative in forming medical product distribution streams in the U.S.,” said Alan Donze, Bioretec CEO. “The initial controlled launch of RemeOs trauma screws in the U.S. yielded excellent patient results, with a notable number of surgeries and successful post-healing follow-ups. This success lays the groundwork for entering the second phase of commercialization for RemeOs products in the U.S. and driving demand within the surgeon community.
New distribution deals come more than a year after the company acquired a new CNC machining center to increase production capacity. The acquisition is optimized for the production of magnesium-based implants, including RemeOs. Bioretec’s RemeOs screw received FDA approval in March.
RemeOs implants are resorbed and replaced by bone, eliminating the need for removal surgery while facilitating healing.
